Lemaitre Vascular (LMAT) is Strengthening Profitability in Vascular Disease Treatment

2 hours ago 1

Soumya Eswaran

Tue, April 28, 2026 astatine 9:21 AM CDT 3 min read

Conestoga Capital Advisors, an plus absorption company, released its first-quarter 2026 capitalist letter. A transcript of the missive tin beryllium downloaded here. The archetypal 4th of 2026 began with optimism astir the home system and charismatic Small Cap valuations, but was impacted by volatility from Middle East geopolitical unrest and changing involvement complaint expectations. This unrest drove vigor prices up and created cautious planetary markets. Energy, Basic Materials, and Industrials performed well, portion bundle companies faced challenges owed to AI disruption concerns. Market sensitivity to geopolitical events, vigor prices, and ostentation remains high. The Conestoga Small Cap Composite fell 5.01%, underperforming the Russell 2000 Growth’s -2.81% return. The diminution was driven by antagonistic banal enactment and headwinds successful Technology and Health Care, with assemblage allocation benefits insufficient to offset losses. In addition, delight cheque the Strategy’s apical 5 holdings to cognize its champion picks successful 2026.

In its first-quarter 2026 capitalist letter, Conestoga Capital Advisors highlighted LeMaitre Vascular, Inc. (NASDAQ:LMAT) arsenic a starring contributor. LeMaitre Vascular, Inc. (NASDAQ:LMAT) is simply a aesculapian instrumentality institution focusing connected the manufacturing and improvement of products and services for vascular surgery. On April 27, 2026, LeMaitre Vascular, Inc. (NASDAQ:LMAT) closed astatine $114.52 per share. One-month instrumentality of LeMaitre Vascular, Inc. (NASDAQ:LMAT) was 4.90%, and its shares gained 23.67% implicit the past 52 weeks. LeMaitre Vascular, Inc. (NASDAQ:LMAT) has a marketplace capitalization of $2.62 billion.

Conestoga Capital Advisors stated the pursuing regarding LeMaitre Vascular, Inc. (NASDAQ:LMAT) successful its Q1 2026 capitalist letter:

"LeMaitre Vascular, Inc. (NASDAQ:LMAT) develops and manufactures devices for the attraction of vascular disease. The 4th reinforced the company’s quality to consistently person dependable procedure-driven request into outsized nett growth, supported by pricing and disciplined disbursal management. Operating leverage was the cardinal operator of the stock, with operating income expanding 47% connected mid-teens gross growth. Investors rewarded the operation of dependable execution and precocious visibility successful a volatile market."

“A Great Under-the-Radar Medical Device Stock”

LeMaitre Vascular, Inc. (NASDAQ:LMAT) is not connected our database of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 22 hedge money portfolios held LeMaitre Vascular, Inc. (NASDAQ:LMAT) astatine the extremity of the 4th quarter, up from 18 successful the erstwhile quarter. While we admit the imaginable of LeMaitre Vascular, Inc. (NASDAQ:LMAT) arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

Read Entire Article